BioSpace News Archive

Syros Pharmaceuticals, a leader in the development of medicines that control the expression of genes, announced the grant of restricted stock unit awards for an aggregate of 48,400 shares of Syros common stock to two newly hired employees in connection with their commencement of employment with Syros.

Cullinan Oncology, Inc. announced that the compensation committee of the Company’s Board of Directors granted stock option awards to purchase an aggregate of 70,000 shares of its common stock to two employees outside Cullinan Oncology, Inc’s 2021 Stock Option and Incentive Plan.

G1 Therapeutics, Inc., a commercial-stage oncology company, announced the grant of inducement stock options exercisable for 40,400 shares of G1’s common stock and 26,800 restricted stock units to six hired employees under the Amended and Restated G1 Therapeutics, Inc. 2021 Inducement Equity Incentive Plan.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it has completed the acquisition of Sanofi’s stake in Libtayo® (cemiplimab), providing Regeneron with exclusive worldwide development, commercialization, and manufacturing rights to the medicine originally discovered in Regeneron’s laboratories.

Biomea Fusion, Inc. (Nasdaq: BMEA), announced today that two BMF-219 preclinical abstracts were chosen for oral presentations at the European Association for the Study of Diabetes (EASD) Annual Meeting.

Centessa Pharmaceuticals plc (Nasdaq: CNTA), today announced the appointment of Mathias Hukkelhoven, Ph.D., formerly Senior Vice President, Global Regulatory, Safety & Biometrics at Bristol Myers Squibb (BMS), to its Board of Directors.

Vaxart, Inc. urges its stockholders of record on April 11, 2022, to vote on its proxy if they have not yet done so.

IgGenix, Inc., a biotechnology company taking a revolutionary approach to directly alleviate allergic disease, today announced insights from its novel SeqSifter™ single-cell RNA-sequencing discovery platform demonstrating the potential for IgE antibody re-engineering in tree nut allergy.

Recent Publications By Kuick Research Highlights Emergence Of Antibodies As Fundamental Premise For The Growth Of Targeted Cancer Drug Market Market.